Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... one of a lengthening list of pharma companies that are hoping to hit on effective 'me ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Securing a prescription for GLP-1s can be pricey — and not to mention, sometimes quite frustrating and invasive. But safety ...

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...

If you’ve been trying to reach a healthier weight, you may be considering semaglutide medications like Ozempic and Wegovy.

Auchincloss said he wants to see Congress “delink” PBMs’ service fees from a drug’s list price and ... animals are at “higher ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.